--- title: "12 Health Care Stocks Moving In Wednesday's Pre-Market Session" type: "News" locale: "en" url: "https://longbridge.com/en/news/285377120.md" description: "In Wednesday's pre-market session, Avalo Therapeutics (AVTX) saw a significant gain of 50.9%, reaching $24.53, while GlucoTrack (GCTK) rose by 45.2% to $1.06. Other notable gainers included Simulations Plus (SLP) up 35.66% and MannKind (MNKD) up 20.27%. Conversely, PAVmed (PAVM) dropped 27.9% to $5.8, and Apimeds Pharmaceuticals (APUS) fell 27.67% to $2.17. TransMedics Group (TMDX) and Akanda (AKAN) also experienced declines of 22.04% and 19.22%, respectively. The fluctuations follow recent earnings reports for Q1 and Q4." datetime: "2026-05-06T12:06:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285377120.md) - [en](https://longbridge.com/en/news/285377120.md) - [zh-HK](https://longbridge.com/zh-HK/news/285377120.md) --- # 12 Health Care Stocks Moving In Wednesday's Pre-Market Session ### Gainers - **Avalo Therapeutics** (NASDAQ:AVTX) stock moved upwards by 50.9% to $24.53 during Wednesday's pre-market session. The company's market cap stands at $370.5 million. - **GlucoTrack** (NASDAQ:GCTK) stock moved upwards by 45.2% to $1.06. The market value of their outstanding shares is at $2.6 million. - **Simulations Plus** (NASDAQ:SLP) shares increased by 35.66% to $21.31. The market value of their outstanding shares is at $317.4 million. - **MannKind** (NASDAQ:MNKD) stock moved upwards by 20.27% to $3.44. The market value of their outstanding shares is at $869.0 million. As per the news, the Q1 earnings report came out today. - **Cypherpunk Technologies** (NASDAQ:CYPH) shares increased by 19.65% to $1.28. The company's market cap stands at $104.5 million. - **Atlantic International** (NASDAQ:ATLN) shares rose 17.32% to $1.49. The company's market cap stands at $100.7 million. ### Losers - **PAVmed** (NASDAQ:PAVM) shares decreased by 27.9% to $5.8 during Wednesday's pre-market session. The company's market cap stands at $58.5 million. - **Apimeds Pharmaceuticals** (AMEX:APUS) stock declined by 27.67% to $2.17. The market value of their outstanding shares is at $37.7 million. As per the press release, Q4 earnings came out 2 days ago. - **TransMedics Group** (NASDAQ:TMDX) stock declined by 22.04% to $74.01. The market value of their outstanding shares is at $3.2 billion. As per the press release, Q1 earnings came out yesterday. - **Akanda** (NASDAQ:AKAN) shares fell 19.22% to $24.24. The company's market cap stands at $16.0 million. - **Hyperion DeFi** (NASDAQ:HYPD) stock decreased by 18.63% to $3.8. The market value of their outstanding shares is at $38.1 million. - **Alphatec Holdings** (NASDAQ:ATEC) shares fell 17.01% to $8.49. The market value of their outstanding shares is at $1.5 billion. The company's, Q1 earnings came out yesterday. **See Also:** www.benzinga.com/money/best-healthcare-stocks/ This article was generated by Benzinga's automated content engine and reviewed by an editor. ### Related Stocks - [AVTX.US](https://longbridge.com/en/quote/AVTX.US.md) - [APUS.US](https://longbridge.com/en/quote/APUS.US.md) - [TMDX.US](https://longbridge.com/en/quote/TMDX.US.md) - [PAVM.US](https://longbridge.com/en/quote/PAVM.US.md) - [AKAN.US](https://longbridge.com/en/quote/AKAN.US.md) - [SLP.US](https://longbridge.com/en/quote/SLP.US.md) - [MNKD.US](https://longbridge.com/en/quote/MNKD.US.md) - [GCTK.US](https://longbridge.com/en/quote/GCTK.US.md) - [CYPH.US](https://longbridge.com/en/quote/CYPH.US.md) - [ATLN.US](https://longbridge.com/en/quote/ATLN.US.md) - [HYPD.US](https://longbridge.com/en/quote/HYPD.US.md) - [ATEC.US](https://longbridge.com/en/quote/ATEC.US.md) - [SQLLW.US](https://longbridge.com/en/quote/SQLLW.US.md) - [PAVMZ.US](https://longbridge.com/en/quote/PAVMZ.US.md) ## Related News & Research - [Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16](https://longbridge.com/en/news/286945953.md) - [PAVmed Reports Q1 2026 Results and Business Update](https://longbridge.com/en/news/286567652.md) - [These Analysts Revise Their Forecasts On Avalo Therapeutics After Q1 Results](https://longbridge.com/en/news/286424446.md) - [Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty](https://longbridge.com/en/news/286366040.md) - [Avalo Therapeutics Q1 net loss widens on increased R&D spend](https://longbridge.com/en/news/286249018.md)